NHS-Modified MMAF (TFA)

CAT:
804-HY-139325A-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
NHS-Modified MMAF (TFA) - image 1

NHS-Modified MMAF (TFA)

  • Description :

    NHS-Modified MMAF (intermediat 210) TFA is an intermediate which can be used for producing the anti-mesothelin binder-agent conjugates (ADCs) [1].
  • UNSPSC :

    12352203
  • Target :

    Drug-Linker Conjugates for ADC
  • Related Pathways :

    Antibody-drug Conjugate/ADC Related
  • Field of Research :

    Cancer
  • Purity :

    96.03
  • Smiles :

    O=C(N1CCCCO1)[C@@H](NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCCCC(ON3C(CCC3=O)=O)=O)=O)=O)=O)OC)=O)CC4=CNC5=CC=CC=C45.OC(C(F)(F)F)=O
  • Molecular Formula :

    C57H87F3N8O14
  • Molecular Weight :

    1165.34
  • References & Citations :

    [1]Lerchen HG, et, al. Novel binder-drug conjugates (adcs) and their use. WO2012143499A2.
  • Shipping Conditions :

    Blue Ice
  • Storage Conditions :

    -20°C (Powder, protect from light, stored under nitrogen)
  • Scientific Category :

    ADC Related
  • Clinical Information :

    No Development Reported

Featured Selection

Popular Products

Discover our most sought-after biotechnology products, trusted by researchers worldwide